TIDMAGY
RNS Number : 9657H
Allergy Therapeutics PLC
08 December 2020
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Result of Annual General Meeting
8 December 2020 Allergy Therapeutics plc (AIM:AGY), the fully
integrated specialty pharmaceutical group specialising in allergy
vaccines, announces that, with the exception of resolution 10,
which failed to carry, all other resolutions proposed at the 2020
Annual General Meeting ("AGM") were duly passed by shareholders.
Voting was conducted by way of a poll.
Resolutions 1 to 9 (inclusive) were proposed as ordinary
resolutions and resolution 10 was proposed as a special resolution.
The results of the poll are outlined in the table below.
The Board acknowledges the failure to pass resolution 10 and is
disappointed in this outcome. The Board considers the flexibility
afforded by these authorities to be in the best interests of the
Company and shareholders and notes that this resolution has
received support at previous AGMs. However, the Board remains
committed to continuing an open and transparent dialogue and will,
accordingly, seek to continue to engage with shareholders regarding
their views in this area.
Total Votes % of
Resolution For: %age Against: %age Cast ISC Withheld
1. to receive
a copy of the
Annual Report
for the year ended
30 June 2020 556,845,254 100 0 0 556,845,254 87.03 26,857
------------ ------ ------------ ------ ------------ ------ ----------
2. To approve
the Directors'
Remuneration Report 554,801,389 99.64 1,990,053 0.36 556,791,442 87.02 80,669
------------ ------ ------------ ------ ------------ ------ ----------
3. To re-appoint
Manuel Llobet
as a Director 556,845,611 100 0 0 556,845,611 87.03 26,500
------------ ------ ------------ ------ ------------ ------ ----------
4. To re-appoint
Nicolas Wykeman
as a Director 556,821,111 99.99 25,000 0.01 556,846,111 87.03 26,000
------------ ------ ------------ ------ ------------ ------ ----------
5. To re-appoint
Steve Smith as
a Director 554,199,787 99.53 2,636,967 0.47 556,836,754 87.02 35,357
------------ ------ ------------ ------ ------------ ------ ----------
6. To re-appoint
Peter Jensen as
a Director 554,200,287 99.6 2,211,900 0.4 556,412,187 86.96 459,924
------------ ------ ------------ ------ ------------ ------ ----------
7. To re-appoint
Grant Thornton
LLP as auditors
of the Company 554,851,201 99.64 2,007,553 0.36 556,858,754 87.03 13,357
------------ ------ ------------ ------ ------------ ------ ----------
8. To authorise
the Directors
to determine the
Auditors remuneration 556,787,942 99.99 25,000 0.01 556,812,942 87.02 59,169
------------ ------ ------------ ------ ------------ ------ ----------
9. To authorise
the Directors
to allot the unissued
share capital
up to a specified
amount (s.551) 281,855,864 50.8 272,997,694 49.2 554,853,558 86.71 2,018,553
------------ ------ ------------ ------ ------------ ------ ----------
10. Special Resolution:
To disapply pre-emption
provisions of
s.561(1) of the
Companies Act
2006 up to a specified
amount 281,828,810 50.61 274,980,390 49.39 556,809,200 87.02 62,911
------------ ------ ------------ ------ ------------ ------ ----------
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Deardon, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia
Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical group focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines, that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.600 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGKKFBQQBDDDBK
(END) Dow Jones Newswires
December 08, 2020 09:42 ET (14:42 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024